The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination
Open accessAbstract
Neisseria meningitidis is a major cause of bacterial meningitis and septicaemia worldwide and is associated with high case fatality rates and serious life-long complications among survivors. Twelve serogroups are recognised, of which six (A, B, C, W, X and Y) are responsible for nearly all cases of invasive meningococcal disease (IMD). The incidence of IMD and responsible serogroups vary widely both geographically and over time. For the first time, effective vaccines against all these serogroups are available or nearing licensure. Over the past two decades, IMD incidence has been declining across most parts of the world through a combination of successful meningococcal immunisation programmes and secular trends. The introduction of meningococcal C conjugate vaccines in the early 2000s was associated with rapid declines in meningococcal C disease, whilst implementation of a meningococcal A conjugate vaccine across the African meningitis belt led to near-elimination of meningococcal A disease. Consequently, other serogroups have become more important causes of IMD. In particular, the emergence of a hypervirulent meningococcal group W clone has led many countries to shift from monovalent meningococcal C to quadrivalent ACWY conjugate vaccines in their national immunisation programmes. Additionally, the recent licensure of two protein-based, broad-spectrum meningococcal B vaccines finally provides protection against the most common group responsible for childhood IMD across Europe and Australia. This review describes global IMD epidemiology across each continent and trends over time, the serogroups responsible for IMD, the impact of meningococcal immunisation programmes and future needs to eliminate this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petousis-Harris, H., Paynter, J., Morgan, J., Saxton, P., McArdle, B., Goodyear-Smith, F., & Black, S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31449-6 · Cited by 457
Global epidemiology of invasive meningococcal disease
Jafri, R. Z., Ali, A., Messonnier, N. E., Tevi-Benissan, C., Durrheim, D., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M., Sow, S., et al. (2013) · Population Health Metrics · doi:10.1186/1478-7954-11-17 · Cited by 372
Self-citationTappero, J. W., Lagos, R., Maldonado Ballesteros, A., Plikaytis, B., Williams, D., Dykes, J., Gheesling, L. L., Carlone, G. M., Høiby, E. A., Holst, J., et al. (1999) · JAMA · doi:10.1001/jama.281.16.1520 · Cited by 369
Cohn, A. C., MacNeil, J. R., Harrison, L. H., Hatcher, C., Theodore, J., Schmidt, M., Pondo, T., Arnold, K. E., Baumbach, J., Bennett, N., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649209 · Cited by 345
Self-citationParikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31921-3 · Cited by 275
Self-citationBorrow, R., Alarcón, P., Carlos, J., Caugant, D. A., Christensen, H., Debbag, R., De Wals, P., Echániz-Aviles, G., Findlow, J., Head, C., et al. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1258308 · Cited by 269
Self-citationAdvances in the Development of Vaccines against Neisseria meningitidis
Tan, L. K. K., Carlone, G. M., & Borrow, R. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0906357 · Cited by 233
Self-citationHolst, J., Oster, P., Arnold, R., Tatley, M., Næss, L., Aaberge, I., Galloway, Y., McNicholas, A., O'Hallahan, J., Rosenqvist, E., et al. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24129 · Cited by 225
Lucidarme, J., Hill, D. M. C., Bratcher, H. B., Gray, S. J., du Plessis, M., Tsang, R. S. W., Vazquez, J. A., Taha, M.-K., Ceyhan, M., Efron, A. M., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.07.007 · Cited by 225
Self-citationCampbell, H., Andrews, N., Borrow, R., Trotter, C., & Miller, E. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00529-09 · Cited by 213
Self-citationWang, B., Santoreneos, R., Giles, L., Haji Ali Afzali, H., & Marshall, H. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.020 · Cited by 211
Self-citationVaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
Ladhani, S. N., Andrews, N., Parikh, S. R., Campbell, H., White, J., Edelstein, M., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901229 · Cited by 210
Self-citationLadhani, S. N., Beebeejaun, K., Lucidarme, J., Campbell, H., Gray, S., Kaczmarski, E., Ramsay, M. E., & Borrow, R. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu881 · Cited by 207
Self-citationViner, R. M., Booy, R., Johnson, H., Edmunds, W. J., Hudson, L., Bedford, H., Kaczmarski, E., Rajput, K., Ramsay, M., & Christie, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70180-1 · Cited by 201
Self-citationPelton, S. I. (2016) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2016.04.012 · Cited by 199
Whalen, C. M. (1995) · JAMA · doi:10.1001/jama.273.5.390 · Cited by 195
Acevedo, R., Bai, X., Borrow, R., Caugant, D. A., Carlos, J., Ceyhan, M., Christensen, H., Climent, Y., De Wals, P., Dinleyici, E. C., et al. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1557520 · Cited by 191
Self-citationMeningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia
Marshall, H. S., McMillan, M., Koehler, A. P., Lawrence, A., Sullivan, T. R., MacLennan, J. M., Maiden, M. C. J., Ladhani, S. N., Ramsay, M. E., Trotter, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1900236 · Cited by 189
Self-citationThe epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
Whittaker, R., Dias, J. G., Ramliden, M., Ködmön, C., Economopoulou, A., Beer, N., Pastore Celentano, L., Kanitz, E., Richter, L., Mattheus, W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.007 · Cited by 179
Self-citationMeningococcal disease: changes in epidemiology and prevention
Stephens, D. S., Chang, Q., & Tzeng (2012) · Clinical Epidemiology · doi:10.2147/clep.s28410 · Cited by 167
The Meningitis Vaccine Project
LaForce, F. M., Konde, K., Viviani, S., & Préziosi, M.-P. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.049 · Cited by 158
Current Epidemiology and Trends in Meningococcal Disease—United States, 1996–2015
MacNeil, J. R., Blain, A. E., Wang, X., & Cohn, A. C. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix993 · Cited by 140
Brooks, R., Woods, C. W., Benjamin, Jr., & Rosenstein, N. E. (2006) · Clinical Infectious Diseases · doi:10.1086/504804 · Cited by 124
ASHTON, F. E., Ryan, J. A., Borczyk, A. A., Caugant, D. A., Mancino, L. J. C., & Huang, D. (1991) · Journal of Clinical Microbiology · doi:10.1128/jcm.29.11.2489-2493.1991 · Cited by 121
Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand
Arnold, R., Galloway, Y., McNicholas, A., & O’Hallahan, J. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.120 · Cited by 113
Lucidarme, J., Scott, K. J., Ure, R., Smith, A. H., Lindsay, D., Stenmark, B., Jacobsson, S., Fredlund, H., Cameron, J. C., Smith‐Palmer, A., et al. (2016) · Eurosurveillance · doi:10.2807/1560-7917.es.2016.21.45.30395 · Cited by 113
Self-citationBooy, R., de Gentile, A. S., Nissen, M. D., Whelan, J., & Abitbol, V. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1532248 · Cited by 111
A Prospective Study of the Effectiveness of the New Zealand Meningococcal B Vaccine
Kelly, C., Arnold, R., Galloway, Y., & O'Hallahan, J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm147 · Cited by 109
MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine
Medini, D., Stella, M., & Wassil, J. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.04.015 · Cited by 105
Enter B and W: two new meningococcal vaccine programmes launched
Ladhani, S. N., Ramsay, M. E., Borrow, R., Riordan, A. I., Watson, J. M., & Pollard, A. J. (2015) · Archives of Disease in Childhood · doi:10.1136/archdischild-2015-308928 · Cited by 103
Self-citationMustapha, M. M., Marsh, J. W., & Harrison, L. H. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.02.014 · Cited by 103
Self-citationVaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000
McIntyre, P. B., Gidding, H. F., Gilmour, R. E., Lawrence, G. L., Hull, B. P., Horby, P., Wang, H., Andrews, R. M., & Burgess, M. A. (2002) · Communicable Diseases Intelligence · doi:10.33321/cdi.2002.26.12 · Cited by 96
Meningococcal B vaccine (4CMenB): the journey from research to real world experience
Rappuoli, R., Pizza, M., Masignani, V., & Vadivelu, K. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1547637 · Cited by 94
Chen, W. H., Neuzil, K. M., Boyce, C., Pasetti, M. F., Reymann, M. K., Martellet, L., Hosken, N. A., LaForce, F. M., Dhere, R. M., Pisal, S. S., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30400-6 · Cited by 89
Self-citationTaha, M., Claus, H., Lappann, M., Veyrier, F. J., Otto, A., Becher, D., Deghmane, A., Frosch, M., Hellenbrand, W., Hong, E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154047 · Cited by 87
Campbell, H. J., Edelstein, M. L., Andrews, N. J., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2017) · Emerging infectious diseases · doi:10.3201/eid2307.170236 · Cited by 85
Self-citationEffectiveness and Duration of Protection of One Dose of a Meningococcal Conjugate Vaccine
Cohn, A. C., MacNeil, J. R., Harrison, L. H., Lynfield, R., Reingold, A. L., Schaffner, W., Zell, E. R., Plikaytis, B. D., Wang, X., Messonnier, N. E., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2016-2193 · Cited by 83
Self-citationGlobal incidence of serogroup B invasive meningococcal disease: a systematic review
Sridhar, S., Greenwood, B. M., Head, C., Plotkin, S. A., Sáfadi, M. A. P., Saha, S. K., Taha, M., Tomori, O., & Gessner, B. D. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00217-0 · Cited by 80
Borrow, R., Caugant, D. A., Ceyhan, M., Christensen, H., Dinleyici, E. Ç., Findlow, J., Glennie, L., von Gottberg, A., Kechrid, A., Moreno, J. V., et al. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.04.007 · Cited by 78
Self-citationVaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges
Mustapha, M. M., & Harrison, L. H. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1412020 · Cited by 77
Self-citationThe Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada
Bettinger, J. A., Scheifele, D. W., Saux, N. L., Halperin, S. A., Vaudry, W., & Tsang, R. S. W. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819040e7 · Cited by 76
Self-citationMeningococcal disease in Asia: an under-recognized public health burden
Vyse, A., Wolter, J. M., CHEN, J., et al. (2011) · Epidemiology and Infection · doi:10.1017/s0950268811000574 · Cited by 76
Wals, P. D., Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Law, D. K. S., Serres, G. D., Gîlca, V., Gilca, R., & Boulianne, N. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix154 · Cited by 74
Global practices of meningococcal vaccine use and impact on invasive disease
Ali, A., Jafri, R. Z., Messonnier, N. E., Tévi‐Bénissan, C., Dürrheim, D. N., Eskola, J., Fermon, F., Klugman, K. P., Ramsay, M. E., Sow, S. O., et al. (2014) · Pathogens and Global Health · doi:10.1179/2047773214y.0000000126 · Cited by 72
Self-citationPerez, J. L., Absalon, J., Beeslaar, J. F., Balmer, P., Jansen, K. U., Jones, T. R., Harris, S. L., York, L. J., Jiang, Q. L., Radley, D. R., et al. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1483726 · Cited by 69
Wall, E. C., Everett, D., Mukaka, M., Bar‐Zeev, N., Feasey, N., Jahn, A., Moore, M., van Oosterhout, J. J., Pensalo, P., Baguimira, K., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu057 · Cited by 66
Yezli, S. (2018) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2018.05.003 · Cited by 64
Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Betala-Belinga, J.-F., Serres, G. D., & Wals, P. D. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.06.021 · Cited by 62
Bryan, P. T., Seabroke, S., Wong, J., Donegan, K. L., Webb, E., Goldsmith, C., Vipond, C., & Feavers, I. M. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30103-2 · Cited by 61
Petousis‐Harris, H., & Radcliff, F. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00683 · Cited by 61
Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006–2015
du Châtelet, I. P., Deghmane, A., Antona, D., Hong, E., Fonteneau, L., Taha, M., & Lévy-Bruhl, D. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.02.011 · Cited by 60
Li, J., Shao, Z., Liu, G., Bai, X., Borrow, R., Chen, M., Guo, Q., Han, Y., Li, Y., Taha, M., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.01.007 · Cited by 59
Self-citationBai, X., Borrow, R., Bukovski, S., Caugant, D. A., Culic, D., Delic, S., Dinleyici, E. Ç., Eloshvili, M., Erdősi, T., Galajeva, J., et al. (2019) · Journal of Infection · doi:10.1016/j.jinf.2019.10.018 · Cited by 48
Self-citationParikh, S. R., Campbell, H. J., Gray, S. J., Beebeejaun, K., Ribeiro, S., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.038 · Cited by 47
Self-citationVaccine Preventable Diseases and Vaccination Coverage in Australia, 2001 to 2002
Brotherton, J., McIntyre, P., Puech, M., Wang, H., Gidding, H., Hull, B., Lawrence, G., MacIntyre, R., Wood, N., & Armstrong, D. (2004) · Communicable Diseases Intelligence · doi:10.33321/cdi.2004.28.65 · Cited by 46
Adoption of Serogroup B Meningococcal Vaccine Recommendations
Kempe, A., Allison, M. A., MacNeil, J. R., O’Leary, S. T., Crane, L. A., Beaty, B. L., Hurley, L. P., Brtnikova, M., Lindley, M. C., & Albert, A. P. (2018) · PEDIATRICS · doi:10.1542/peds.2018-0344 · Cited by 46
Continuing Effectiveness of Serogroup A Meningococcal Conjugate Vaccine, Chad, 2013
Gamougam, K., Daugla, D. M., Toralta, J., Ngadoua, C., Fermon, F., Page, A., Djingarey, M. H., Caugant, D. A., Manigart, O., Trotter, C. L., et al. (2014) · Emerging infectious diseases · doi:10.3201/eid2101.140256 · Cited by 45
Andrade, A. L., Minamisava, R., Tomich, L. G. M. D. M., de Lemos, A. P. S., Gorla, M. C., Brandileone, M. C. D. C., Domingues, C. M. S., de Moraes, C., Policena, G. M., Bierrenbach, A. L., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.010 · Cited by 45
Archer, B. N., Chiu, C. K., Jayasinghe, S. H., Richmond, P., McVernon, J., Lahra, M. M., Andrews, R. M., & McIntyre, P. B. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.01340 · Cited by 45
Kinlin, L. M., Jamieson, F., Brown, E. M., Brown, S., Rawte, P., Dolman, S., Drews, S. J., & Fisman, D. N. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.026 · Cited by 44
Dyet, K. H., DEVOY, A., McDowell, R., & Martin, D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.050 · Cited by 42
The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012
Sadarangani, M., Scheifele, D. W., Halperin, S. A., Vaudry, W., Saux, N. L., Tsang, R. S. W., Bettinger, J. A., Bridger, N. A., Morris, R., Halperin, S. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu597 · Cited by 42
Self-citationKim, S. A., Kim, D. W., Dong, B. Q., Kim, J. S., Anh, Đ. Đ., & Kilgore, P. E. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-310 · Cited by 40
Epidemiology of Meningococcal Disease Outbreaks in the United States, 2009–2013
Mbaeyi, S. A., Blain, A. E., Whaley, M. J., Wang, X., Cohn, A. C., & MacNeil, J. R. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy548 · Cited by 38
Harris, S. L., Tan, C., Andrew, L., Li, H., Liberator, P., Absalon, J., Anderson, A. S., & Jones, T. R. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.081 · Cited by 37
Epidemiological burden of meningococcal disease in Latin America: A systematic literature review
Presa, J. V., Abalos, M. G., de Almeida, R. S., & Cane, A. D. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.05.006 · Cited by 36
Incidence and Prevention of Invasive Meningococcal Disease in Global Mass Gathering Events
Muttalif, A. R., Presa, J. V., Haridy, H., Gamil, A., Serra, L., & Cane, A. D. (2019) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00262-9 · Cited by 36
Villena, R., Valenzuela, M. T., Bastías, M., & Santolaya, M. E. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.09.050 · Cited by 36
Etiologies of Bacterial Meningitis in Bangladesh: Results from a Hospital-Based Study
Gurley, E. S., Hossain, M. J., Montgomery, S. P., Petersen, L. R., Sejvar, J. J., Mayer, L. W., Whitney, A. M., Dull, P. M., Nahar, N., Uddin, A. K. M. R., et al. (2009) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.81.475 · Cited by 34
Australian Meningococcal Surveillance Programme Annual Report, 2023
the National Neisseria Network, A., Lahra, M. M., George, C. R., van Hal, S. J., & Hogan, T. R. (2024) · Communicable Diseases Intelligence · doi:10.33321/cdi.2024.48.52 · Cited by 33
Vaccines for prevention of group B meningococcal disease: Not your father's vaccines
Harrison, L. H. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.101 · Cited by 33
Self-citationAli, M., Chang, B. A., Johnson, K. W., & Morris, S. K. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.07.037 · Cited by 32
Gilca, R., Deceuninck, G., Lefebvre, B., Tsang, R. S. W., Amini, R., Gîlca, V., Douville-Fradet, M., Markowski, F., & Wals, P. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050659 · Cited by 31
Scholz, S. M., Koerber, F., Meszaros, K., Fassbender, R. M., Ultsch, B., Welte, R., & Greiner, W. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.01.013 · Cited by 29
Advances with vaccination against Neisseria meningitidis
Borrow, R. (2012) · Tropical Medicine & International Health · doi:10.1111/j.1365-3156.2012.03085.x · Cited by 26
Self-citationIbarz-Pavón, A. B., Morais, L., Sigaúque, B., Mandomando, I., Bassat, Q., Nhacolo, A., Quintó, L., Soriano‐Gabarró, M., Alonso, P. L., & Roca, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019717 · Cited by 26
Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016
Tsang, R. S. W., Hoang, L., Tyrrell, G., Horsman, G. B., Caeseele, P. G. V., Jamieson, F. B., Lefebvre, B., Haldane, D. J. M., Gad, R., German, G., et al. (2017) · Canada Communicable Disease Report · doi:10.14745/ccdr.v43i78a01 · Cited by 25
Badahdah, A.-M. M., Rashid, H., Khatami, A., & Booy, R. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.06.027 · Cited by 25
Marshall, H. S., Lally, N., Flood, L., & Phillips, P. A. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50481 · Cited by 25
Self-citationTsang, R. S. W., Ahmad, T., Tyler, S., Lefebvre, B., Deeks, S. L., Gilca, R., Hoang, L., Tyrrell, G. J., Caeseele, P. G. V., Domselaar, G. V., et al. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.01.019 · Cited by 24
Neisseria meningitidis and meningococcal disease: recent discoveries and innovations
Read, R. C. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000606 · Cited by 24
Safety of a meningococcal group B vaccine used in response to two university outbreaks
Duffy, J., Johnsen, P., Ferris, M., Miller, M. K., Leighton, K., McGilvray, M., McNamara, L. A., Breakwell, L., Yon, Y., Bhavsar, T. R., et al. (2017) · Journal of American College Health · doi:10.1080/07448481.2017.1312418 · Cited by 22
Meningococcal disease surveillance in men who have sex with men—United States, 2015–2016
Bozio, C. H., Blain, A., MacNeil, J., Retchless, A., Weil, L. M., Wang, X., Jenkins, L. T., Rodriguez-Rivera, L. D., Jarashow, C., Ngo, V., et al. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6738a4 · Cited by 21
Mbaeyi, S. A., Cohn, A. C., & Coldiron, M. E. (2018) · Cambridge University Press eBooks · doi:10.1017/9781107477261.028 · Cited by 20
Diallo, K., Gamougam, K., Daugla, D. M., Harrison, O. B., Bray, J. E., Caugant, D. A., Lucidarme, J., Trotter, C. L., Hassan-King, M., Stuart, J. M., et al. (2017) · BMC Genomics · doi:10.1186/s12864-017-3789-0 · Cited by 18
Declining Incidence of Invasive Meningococcal Disease in South Africa: 2003–2016
Meiring, S. T., Cohen, C., de Gouveia, L., du Plessis, M., Kularatne, R. S., Hoosen, A. A., Lekalakala, R., Lengana, S., Seetharam, S., Naicker, P. R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy914 · Cited by 16
van Kessel, F., van den Ende, C., Oordt-Speets, A. M., & Kyaw, M. H. (2019) · Journal of Global Health · doi:10.7189/jogh.09.010411 · Cited by 16
Tsang, R. S. W., Deeks, S. L., Wong, K., Marchand‐Austin, A., & Jamieson, F. (2016) · Canada Communicable Disease Report · doi:10.14745/ccdr.v42i12a06 · Cited by 15
Biolchi, A., Tomei, S., Santini, L., Welsch, J. A., Toneatto, D., Gaitatzis, N., Bai, X., Borrow, R., Giuliani, M. M., Mori, E., et al. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1537756 · Cited by 15
Self-citationIntroduction of a second MenB vaccine into Europe – needs and opportunities for public health
Findlow, J., Nuttens, C., & Kriz, P. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1578217 · Cited by 15
Law, D. K. S., Stoltz, J., Henderson, A. M., & Tsang, R. S. W. (2005) · Canadian Journal of Microbiology · doi:10.1139/w05-085 · Cited by 14
Munguambe, A. M., de Almeida, A. E. C. C., Nhantumbo, A. A., Comé, C. E., Zimba, T. F., Langa, J. P., de Filippis, I., & Gudo, E. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197390 · Cited by 14
Macêdo, L. E. N., Ferreira, V. M., Feitosa, C. A., Nunes, A. M. P. B., Campos, L. C., & Sáfadi, M. A. P. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415682 · Cited by 12
Bennett, D. E., O’Lorcain, P. P., Morgan, S., Cotter, S. M., Cafferkey, M., & Cunney, R. (2019) · Epidemiology and Infection · doi:10.1017/s0950268819000396 · Cited by 11
Vaccines for Prevention of Group B Meningococcal Disease
Harrison, L. H. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.09.007 · Cited by 10
Self-citationWormsbecker, A. E., Wong, K., Jamieson, F. B., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.023 · Cited by 9
Growing evidence supports 4CMenB effectiveness
Ladhani, S. N., Borrow, R., & Andrews, N. J. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30051-3 · Cited by 8
Self-citationMills, C., Sexton, K., & Carter, P. (2013) · PubMed · Cited by 4
Practical Use of Meningococcal Vaccines—Whom and When to Vaccinate
Harrison, L. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55435-0.00007-0 · Cited by 2
Self-citation
Research works printed but not linked: 62
- Dastouri, 2014, Complications of serogroup B meningococcal disease in survivors: a review, Infect Disord Drug Targets, 14, 205, 10.2174/1871526515999150320155614 · doi:10.2174/1871526515999150320155614
- Beebeejaun, 2020, Invasive meningococcal disease: timing and cause of death in England, J Infect doi, 2008
- 2019, Invasive meningococcal disease: Annual Epidemiological Report for 2017, ECfDPaC
- Campbell, 2019, Invasive meningococcal disease as a cause of sudden and unexpected death in a teenager: The public health importance of confirming the diagnosis, J Infect, 78, 323, 10.1016/j.jinf.2018.11.004 · doi:10.1016/j.jinf.2018.11.004
- Beresford, 2017, Quality, immunogenicity and stability of meningococcal serogroup ACWY-CRM197, DT and TT glycoconjugate vaccines, Vaccine35, 3598, 10.1016/j.vaccine.2017.03.066 · doi:10.1016/j.vaccine.2017.03.066
- 2019, Meningococcal Disease
- Krone, 2019, Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017, Euro Surveil, l24
- 2019, Invasive Meningococcal Disease in Ireland, 2018, on HSE HSE
- 2019, Meningococcal B
- Knol, 2017, Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study, Lancet Public Health, 2, e473, 10.1016/S2468-2667(17)30157-3 · doi:10.1016/s2468-2667(17)30157-3
- Hong, 2018, Clonal replacement and expansion among invasive meningococcal isolates of serogroup W in France, J Infect, 76, 149, 10.1016/j.jinf.2017.10.015 · doi:10.1016/j.jinf.2017.10.015
- Soeters, 2019, University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013-2018, Emerg Infect Dis, 25, 434, 10.3201/eid2503.181574 · doi:10.3201/eid2503.181574
- Fiorito, 2017, Rapid response to a college outbreak of meningococcal serogroup B disease: Nation's first widespread use of bivalent rLP2086 vaccine, J Am Coll Health, 65, 294, 10.1080/07448481.2017.1285772 · doi:10.1080/07448481.2017.1285772
- Law, 2006, Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19), J Clin Microbiol, 44, 2743, 10.1128/JCM.00601-06 · doi:10.1128/jcm.00601-06
- Bettinger JAS M, Morris S, Le Saux N, Top K, Vaudry W, Halperin S, Tsang R, 2018. Poster P59. The effect of quadrivalent vaccination programs in Canada; September 23-28, 2018., abstr International Pathogenic Neisseria Conference (IPNC), Asilomar, USA.
- Langley, 2016, Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network study, Vaccine34, 4046, 10.1016/j.vaccine.2016.06.025 · doi:10.1016/j.vaccine.2016.06.025
- Bettinger, 2013, The disease burden of invasive meningococcal serogroup B disease in Canada, Pediatr Infect Dis J, 32, e20, 10.1097/INF.0b013e3182706b89 · doi:10.1097/inf.0b013e3182706b89
- Safadi, 2015, The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations, Vaccine33, 6529, 10.1016/j.vaccine.2015.10.055 · doi:10.1016/j.vaccine.2015.10.055
- 2018, Regional Inform from SIREVA II, 2015. Data by country and by age Group on characteristics of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis isolates in invasive bacterial infections, on Organización Panamericana de la Salud
- 2019, Notifiable Diseases Information System – Sinan
- Bakira, 2018, Update on meningococcal disease and its prevention, Rev Hosp Niños, 60, 42
- 2019, Bacterial meningitis and meningococcal disease
- Chacon-Cruz, 2019, Pediatric meningitis due to Neisseria meningitidis, Streptococcus pneumoniae and Group B Streptococcus in Tijuana, Mexico: active/prospective surveillance, 2005-2018, Ther Adv Infect Dis, 6
- Tiffay, 2015, The Evolution of the Meningitis Vaccine Project, Clin Infect Dis 61 Suppl 5, S396, 10.1093/cid/civ594 · doi:10.1093/cid/civ594
- Nnadi, 2017, Large Outbreak of Neisseria meningitidis Serogroup C - Nigeria, December 2016-June 2017, MMWR Morb Mortal Wkly Rep, 66, 1352, 10.15585/mmwr.mm6649a3 · doi:10.15585/mmwr.mm6649a3
- 2016, WHO guidelines for the treatment of Neisseria gonorrhoea
- Shao, 2006, Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China, Lancet, 367, 419, 10.1016/S0140-6736(06)68141-5 · doi:10.1016/s0140-6736(06)68141-5
- Junhong, 2015, Epidemiological Characteristics of Meningococcal Meningitis and Switching Trend of Serogroups of Neisseria meningitidis in China, Chin J Vaccine Immun, 21, 2006
- Juhong, 2019, Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017, Chin J Prev Med, 53, 159
- Zhang, 2016, Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis, J Glob Health, 6, 10.7189/jogh.06.020409 · doi:10.7189/jogh.06.020409
- Zhou, 2013, Spread of Neisseria meningitidis serogroup W clone, China, Emerg Infect Dis, 19, 1496, 10.3201/eid1909.130160 · doi:10.3201/eid1909.130160
- Hu, 2014, Neisseria meningitidis serogroup W135 sequence type 11, Anhui Province, China, 2011-2013, Emerg Infect Dis, 20, 1236, 10.3201/eid2007.131138 · doi:10.3201/eid2007.131138
- Zhang, 2008, Genetic characteristics of serogroup A meningococci circulating in China, 1956-2005, Clin Microbiol Infect, 14, 555, 10.1111/j.1469-0691.2008.01977.x · doi:10.1111/j.1469-0691.2008.01977.x
- Zhou, 2015, Clonal characteristics of invasive Neisseria meningitidis following initiation of an A + C vaccination program in China, J Infect, 70, 2005, 10.1016/j.jinf.2014.07.022 · doi:10.1016/j.jinf.2014.07.022
- Zhu, 2015, Sequence Type 4821 Clonal Complex Serogroup B Neisseria meningitidis in China, 1978-2013, Emerg Infect Dis, 21, 925, 10.3201/eid2106.140687 · doi:10.3201/eid2106.140687
- Shao, 2010, Neisseria meningitidis serogroup W135, China, Emerg Infect Dis, 16, 348, 10.3201/eid1602.090901 · doi:10.3201/eid1602.090901
- Zhu, 2020, Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates, J Infect, 80, 54, 10.1016/j.jinf.2019.08.019 · doi:10.1016/j.jinf.2019.08.019
- Zhu, 2019, Comparative genomic analyses of Chinese serogroup W ST-11 complex Neisseria meningitidis isolates, J Infect doi
- Chen, 2008, A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China, Chin Med J (Engl), 121, 664, 10.1097/00029330-200804010-00017 · DOI
- Pan, 2014, The case of a new sequence type 7 serogroup X Neisseria meningitidis infection in China: may capsular switching change serogroup profile?, Int J Infect Dis, 29, 62, 10.1016/j.ijid.2014.07.022 · doi:10.1016/j.ijid.2014.07.022
- Zhu, 2017, Genetic Analysis of Neisseria meningitidis Sequence Type 7 Serogroup X Originating from Serogroup A, Infect Immun, 85, 10.1128/IAI.01019-16 · doi:10.1128/iai.01019-16
- Li, 2019, The molecular characteristics of Neisseria meningitidis serogroup Y clonal complex 23 first emerge in China, J Infect doi, 10.1016/j.jinf.2019.07.001 · doi:10.1016/j.jinf.2019.07.001
- Fukusumi, 2016, National surveillance for meningococcal disease in Japan, Vaccine34, 1999
- John, 2013, An overview of meningococcal disease in India: knowledge gaps and potential solutions, Vaccine31, 2731, 10.1016/j.vaccine.2013.04.003 · doi:10.1016/j.vaccine.2013.04.003
- Sinclair, 2010, The epidemiology of meningococcal disease in India, Trop Med Int Health, 15, 1421, 10.1111/j.1365-3156.2010.02660.x · doi:10.1111/j.1365-3156.2010.02660.x
- Taj, 2016, Detection of meningococcal meningitis in cerebrospinal fluid of patients with neurological disorders in government hospitals of Karachi, J Pak Med Assoc, 66, 1418
- Hossain, 2009, Increasing isolations of Neisseria meningitides serogroup A from blood and cerebrospinal fluid in Dhaka, Bangladesh, 1999-2006, Am J Trop Med Hyg, 80, 615, 10.4269/ajtmh.2009.80.615 · doi:10.4269/ajtmh.2009.80.615
- 2019, Australia's notifiable diseases status, 2015: Annual report of the National Notifiable Diseases Surveillance System (NNDSS), Commun Dis Intell, 43, 1
- 2019, Meningococcal Disease
- 2019, Disease notification rates, Australia, 1991 to 2018 and year-to-date notifications for 2019, on Australian Government Department of Health
- 2018, Invasive Meningococcal Disease National Surveillance Report - With a focus on MenW - 31 March 2018, on Australian Government Department of Health
- Lahra, 2013, Australian Meningococcal Surveillance Programme annual report, 2012, Commun Dis Intell Q Rep, 37, E224, 10.33321/cdi.2013.37.34 · doi:10.33321/cdi.2013.37.34
- Lahra, 2014, Australian Meningococcal Surveillance Programme annual report, 2013, Commun Dis Intell Q Rep, 38, E301, 10.33321/cdi.2014.38.50 · DOI
- Lahra, 2016, Australian Meningococcal Surveillance Programme annual report, 2014, Commun Dis Intell Q Rep, 40, E221, 10.33321/cdi.2016.40.17 · doi:10.33321/cdi.2016.40.17
- Lahra, 2016, Australian Meningococcal Surveillance Programme annual report, 2015, Commun Dis Intell Q Rep, 40, E503, 10.33321/cdi.2016.40.57 · doi:10.33321/cdi.2016.40.57
- Martin, 2016, Rise in invasive serogroup W meningococcal disease in Australia 2013-2015, Commun Dis Intell Q Rep, 40, E454, 10.33321/cdi.2016.40.50 · doi:10.33321/cdi.2016.40.50
- 2019, NOVEMBER 2019 PBAC MEETING – POSITIVE RECOMMENDATIONS
- 2019, Meningococcal disease
- O'Hallahan, 2004, The strategy to control New Zealand's epidemic of group B meningococcal disease, Pediatr Infect Dis J, 23
- Safadi, 2017, Knowing the scope of meningococcal disease in Latin America, Rev Panam Salud Publica, 41, e118
- Tzeng, 2017, Emergence of a new Neisseria meningitidis clonal complex 11 lineage 11.2 clade as an effective urogenital pathogen, Proc Natl Acad Sci U S A, 114, 4237, 10.1073/pnas.1620971114 · doi:10.1073/pnas.1620971114
- Deghmane, 2017, Emergence of meningococci with reduced susceptibility to third-generation cephalosporins, J Antimicrob Chemother, 72, 95, 10.1093/jac/dkw400 · doi:10.1093/jac/dkw400
Cited by
Community-acquired bacterial meningitis.
van de Beek, D., Brouwer, M. C., Koedel, U., & Wall, E. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00883-7 · Cited by 292
Metadata
- Authors
- Parikh, S. R., Campbell, H., Bettinger, J. A., Harrison, L. H., Marshall, H. S., Martinon-Torres, F., Safadi, M. A., Shao, Z., Zhu, B., von Gottberg, A., Borrow, R., Ramsay, M. E., & Ladhani, S. N.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 81
- Issue
- 4
- Pages
- 483-498
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W3033885385
- Cited by
- 274
- References
- 99
- FWCI
- 20.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.